Bausch Health Companies stock (CA0717341071): Toronto-listed pharma name steady as investors eye next earnings date

Bausch Health Companies shares in Canada are trading in a tight range as the market digests the April Q1 2026 earnings miss and looks toward the next expected results date, while insider filings and institutional positions remain in focus.

Bausch Health Companies shares on the Toronto Stock Exchange have been trading around the mid-single-digit Canadian dollar range in late May 2026, with prices quoted near CAD 7.40 as investors reassess the outlook after the latest quarterly update, according to an overview on Ad-hoc-news.de as of 05/30/2026, highlighting the Canadian home-market context for the stock.

The company is also listed on the New York Stock Exchange under the ticker BHC, providing U.S. dollar liquidity alongside its primary Canadian dollar quotation, which keeps Bausch Health Companies within the broader North American pharmaceuticals and medical products universe for domestic and international investors.

On the earnings side, Bausch Health Companies reported its first-quarter 2026 results on 04/29/2026, posting earnings per share of USD 0.78 compared with the MarketBeat consensus estimate of USD 0.81, implying a shortfall of USD 0.03 per share for the period, according to MarketBeat as of 04/29/2026.

Revenue and segment detail for the quarter were disclosed in the companys investor materials, but the headline figure that attracted attention among Canadian and U.S. investors was the modest EPS miss versus expectations, which led to some recalibration of models even though the absolute level of profitability remained positive.

MarketBeat data as of 06/02/2026 indicates that Bausch Health Cos shares recently closed around USD 5.32 on the NYSE on the last regular trading day cited, positioning the stock in the lower single-digit price bracket on the U.S. market.

For investors focused on timing, MarketBeat further notes that the next earnings publication date has not yet been formally confirmed by the company, but based on last years reporting schedule, the platform currently estimates the next release could fall around 07/29/2026, giving the market a provisional timeline for the next set of figures.

In Europe, Bausch Health Companies is also accessible to German investors via secondary trading lines such as Tradegate and other venues, where the stock is typically quoted in euros and tracks the underlying North American price moves on a currency-adjusted basis, offering an additional route for participation alongside the Toronto and New York listings.

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: BHC
• Sector/industry: Pharmaceuticals and medical products
• Headquarters/country: Laval, Canada
• Core markets: North America, Europe and selected international markets
• Key revenue drivers: Eye health, gastrointestinal drugs and dermatology treatments
• Home exchange/listing venue: Toronto Stock Exchange (BHC) - dual-listed on NYSE (BHC)
• Trading currency: CAD, with parallel USD listing

Bausch Health Companies: core business model

Bausch Health Companies operates as a diversified healthcare group centered on branded pharmaceuticals and medical devices, with a revenue mix that leans heavily on eye care, gastrointestinal therapies and dermatology products sold across a broad set of international markets.

Latest quarterly results for Bausch Health Companies at a glance

The most recent full set of numbers for Bausch Health Companies refers to the first quarter of 2026, when the company reported earnings per share of USD 0.78 on 04/29/2026, versus analyst expectations compiled by MarketBeat of USD 0.81 for the same period, resulting in a USD 0.03 differential to consensus on the bottom line.

MarketBeat data as of 06/02/2026 shows that, following those Q1 2026 results, the shares have been changing hands at around USD 5.32 on the NYSE in recent trading, and the site currently lists 07/29/2026 as the estimated date for the next earnings release based on historical reporting patterns, although the company has not formally confirmed that timing.

Conclusion

For now, Bausch Health Companies shares in Canada and the United States are trading in a relatively narrow range as the market absorbs the Q1 2026 earnings miss of USD 0.03 per share versus consensus and awaits clarity on the precise timing of the next results release.

The latest quarterly figures and the provisional late-July 2026 earnings date estimated by MarketBeat provide a roadmap for when the next major information update could arrive, while ongoing discussion among investors centers on whether current valuations already reflect the companys operational profile and balance-sheet considerations ahead of that event.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.